Jpmorgan Chase & CO Verastem, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.33 - $10.44 $2,911 - $92,101	-8,822 Reduced 64.94%	4,763 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.92 - $11.16 $4,941 - $59,940	5,371 Added 65.39%	13,585 $12,000
Q2 2022 Aug 11, 2022	SELL	$1.02 - $1.83 $96,739 - $173,562	-94,843 Reduced 92.03%	8,214 $10,000
Q1 2022 May 11, 2022	BUY	$1.06 - $2.1 $21,027 - $41,657	19,837 Added 23.84%	103,057 $145,000
Q4 2021 Feb 10, 2022	SELL	$2.05 - $3.2 $654,265 - $1.02 Million	-319,154 Reduced 79.32%	83,220 $170,000
Q3 2021 Nov 12, 2021	BUY	$2.54 - $4.07 $1.02 Million - $1.64 Million	402,374 New	402,374 $1.24 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.41B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.